Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01715883 · ClinicalTrials.gov registry record · Phase 2
Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction
A Phase 2 study, sponsored by Gladwin, Mark, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01715883 is a Phase 2 study that was terminated before completion, run by Gladwin, Mark, MD. The registered enrollment target is 3 participants.
The verdict
NCT01715883, a Phase 2 study, was terminated before completion, sponsored by Gladwin, Mark, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase 2 observational nonrandomized pilot investigation to evaluate the safety and efficacy of Sodium Nitrite administration for the reduction of Primary Graft Dysfunction (PGD) in patients undergoing lung transplant. The study will enroll 8 subjects, undergoing lung transplant at the University of Pittsburgh Medical Center (UPMC).
Interventions
- DRUG Sodium Nitrite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01715883
The ClinicalTrials.gov registry entry for NCT01715883 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gladwin, Mark, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sodium Nitrite is the first listed.
NCT01715883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01715883 about?
NCT01715883 is a clinical study titled "Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction". This is a Phase 2 observational nonrandomized pilot investigation to evaluate the safety and efficacy of Sodium Nitrite administration for the reduction of Primary Graft Dysfunction (PGD) in patients undergoing lung transplant. The study will enroll 8 subjects, undergoing lung transplant at the Univ...
What is the current status of trial NCT01715883?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-10. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01715883?
The interventions under investigation include: Sodium Nitrite (DRUG).
Who is sponsoring clinical trial NCT01715883?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.